Top Story

ANRS CO22: SVR4 rates near 100% for sofosbuvir/daclatasvir in genotype 1

April 25, 2015

VIENNA — Patients treated with regimens containing Sovaldi and daclatasvir achieved encouraging 4-week sustained virologic response rates, according to data presented during the Late Breakers session at the 2015 International Liver Congress.

Stanislas Pol, MD, of the Department of Hepatology at Cochin Hopital, the French Institute of Health and Medical Research, the Pasteur Institute and René Descartes University, treated 317 HCV genotype 1 mono-infected patients with 400 mg (sofosbuvir, Gilead)and 60 mg daclatasvir (Bristol-Myers Squibb) without ribavirin and 92 patients with the sofosbuvir/daclatasvir regimen plus 1 g to 1.2 g of ribavirin. The study included 12- and 24-week treatment groups.

Anupama Subramony, MD Meeting News Coverage

Use of PCR among children with acute respiratory infections may reduce resource utilization

April 25, 2015
SAN DIEGO —Among children hospitalized for acute respiratory infections, using real-time PCR testing increased the number of isolation days but reduced antibiotic…
Meeting News Coverage

RUBY-I: Preliminary study shows safety of 3D + ribavirin in CKD

April 25, 2015
VIENNA — A small cohort of patients with chronic kidney disease demonstrated favorable tolerability outcomes with the Viekira Pak, according to data presented…
Meeting News Coverage

REP 2139 found to reduce HBsAg in Caucasians with HBV/HDV coinfection

April 25, 2015
VIENNA — In a phase 2 clinical trial, the nucleic acid polymer REP 2139 reduced hepatitis B surface antigen serum in Caucasian patients with hepatitis B and D…
Meeting News Coverage

BOSON: Sovaldi plus PEG-RBV improved SVR12 in genotype 3 HCV

April 25, 2015
VIENNA — Twelve weeks of therapy with Sovaldi plus peginterferon and ribavirin was associated with 12-week sustained virologic response rates higher than 90% in…
More News Headlines »
CME
Infectious Disease Case Consults

The Patient at Risk for HIV Infection

No commercial support for this activity.

This CME activity will focus on the utilization of PrEP in patients at risk for developing HIV infection supplemented…
More »
Meeting News Coverage Video
VIDEO: Effectiveness of inactivated vs. live flu vaccine currently unclear

VIDEO: Effectiveness of inactivated vs. live flu vaccine currently unclear

April 24, 2015
BETHESDA, Md. — Richard K. Zimmerman, MD, of the University of Pittsburgh, explains the results of his study…
More »
CME
HCV VOICE

HCV VOICE II: Optimizing Virological Outcomes with Integrated HCV Education

This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular…
More »
morganatic-roan